Skip to main content
SpringerLink
Log in
Book cover

Adolescents with Chronic Kidney Disease pp 153–168Cite as

Lupus Nephritis

  • Chapter
  • First Online:

  • 747 Accesses

Abstract

Lupus nephritis in the adolescent is a frequently severe disease with considerable risk for morbidity and mortality. With treatment advances, there has been improved renal and overall survival. However, relapses and other adverse events can be seen. Full diagnostic evaluation and classification of the disease is required to guide optimal treatment. Clinicians should be aware of the comorbidities associated with the disease process and prescribed pharmacotherapy as it can have significant medical and psychosocial effects on the adolescent.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin N Am. 2012;59(2):345–64.

    Article  Google Scholar 

  2. Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90(3):493–501.

    Article  CAS  Google Scholar 

  3. Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011;13(6):250.

    Article  Google Scholar 

  4. Tarr T, Derfalvi B, Gyori N, Szanto A, Siminszky Z, Malik A, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus. 2015;24(8):796–803.

    Article  CAS  Google Scholar 

  5. Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–76.

    Article  Google Scholar 

  6. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011;20(13):1345–55.

    Article  CAS  Google Scholar 

  7. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.

    Article  CAS  Google Scholar 

  8. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–83.

    Article  Google Scholar 

  9. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2016.

    Google Scholar 

  10. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152–60.

    Article  CAS  Google Scholar 

  11. Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27(10):2929–39.

    Article  CAS  Google Scholar 

  12. Vachvanichsanong P, McNeil E. Pediatric lupus nephritis: more options, more chances? Lupus. 2013;22(6):545–53.

    Article  CAS  Google Scholar 

  13. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25–30.

    Article  CAS  Google Scholar 

  14. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–6.

    Article  Google Scholar 

  15. Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6(9):2192–9.

    Article  CAS  Google Scholar 

  16. Ayalon R, Beck LH Jr. Membranous nephropathy: not just a disease for adults. Pediatr Nephrol. 2015;30(1):31–9.

    Article  Google Scholar 

  17. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.

    Article  Google Scholar 

  18. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  Google Scholar 

  19. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–50.

    Article  Google Scholar 

  20. Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol. 1988;8(2):85–9.

    Article  CAS  Google Scholar 

  21. Rovin BH, Parikh SV, Alvarado A. The kidney biopsy in lupus nephritis: is it still relevant? Rheum Dis Clin N Am. 2014;40(3):537–52. ix

    Article  Google Scholar 

  22. Marks SD, Sebire NJ, Tullus K. Classification of pediatric lupus nephritis. Kidney Int. 2007;72(7):897–8.

    Article  CAS  Google Scholar 

  23. Michail S, Stathakis C, Marinaki S, Revenas C, Nakopoulou L, Vaiopoulos G. Relapse of predominant tubulointerstitial lupus nephritis. Lupus. 2003;12(9):728–9.

    Article  CAS  Google Scholar 

  24. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12.

    Article  CAS  Google Scholar 

  25. Sun F, Wang X, Wu W, Wang K, Chen Z, Li T, et al. TMA secondary to SLE: rituximab improves overall but not renal survival. Clin Rheumatol. 2017;

    Google Scholar 

  26. Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, et al. Lupus nephritis: an update. Clin Exp Nephrol. 2016;20(1):1–13.

    Article  CAS  Google Scholar 

  27. Pons-Estel GJ, Alarcon GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–9.

    Article  CAS  Google Scholar 

  28. Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus. 2013;22(12):1267–73.

    Article  CAS  Google Scholar 

  29. Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic diseases. Arthritis Res Ther. 2011;13(3):222.

    Article  Google Scholar 

  30. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter Suppl. 2012;2:139–274.

    Google Scholar 

  31. Couture J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):488–96.

    Article  CAS  Google Scholar 

  32. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35(5):904–14.

    Article  CAS  Google Scholar 

  33. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study G. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46–53.

    Article  CAS  Google Scholar 

  34. Lenz O, Waheed AA, Baig A, Pop A, Contreras G. Lupus nephritis: maintenance therapy for lupus nephritis – do we now have a plan? Clin J Am Soc Nephrol. 2013;8(1):162–71.

    Article  CAS  Google Scholar 

  35. Hogan J, Appel GB. Update on the treatment of lupus nephritis. Curr Opin Nephrol Hypertens. 2013;22(2):224–30.

    Article  CAS  Google Scholar 

  36. Sundel R, Solomons N, Lisk L, Aspreva Lupus Management Study G. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21(13):1433–43.

    Article  CAS  Google Scholar 

  37. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40.

    Article  Google Scholar 

  38. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95.

    Article  CAS  Google Scholar 

  39. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–26.

    Article  CAS  Google Scholar 

  40. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes – mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010;25(12):3939–48.

    Article  CAS  Google Scholar 

  41. Ward F, Bargman JM. Membranous lupus nephritis: the same, but different. Am J Kidney Dis. 2016;68(6):954–66.

    Article  Google Scholar 

  42. Swan JT, Riche DM, Riche KD, Majithia V. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med. 2011;59(2):246–58.

    Article  CAS  Google Scholar 

  43. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47(11):1678–81.

    Article  CAS  Google Scholar 

  44. Boneparth A, Radhakrishna SM, Greenbaum LA, Yen E, Okamura DM, Cooper JC, et al. Approach to membranous lupus nephritis: a survey of pediatric nephrologists and pediatric rheumatologists. J Rheumatol. 2017;44(11):1619–23.

    Article  Google Scholar 

  45. Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76(11):1788–96.

    Article  Google Scholar 

  46. Beck LH Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J Am Soc Nephrol. 2009;20(4):690–1.

    Article  CAS  Google Scholar 

  47. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001–10.

    Article  CAS  Google Scholar 

  48. Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45(5):604–10.

    Article  CAS  Google Scholar 

  49. Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013;9(1):15–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.

    Article  CAS  Google Scholar 

  51. Hofstra JM, Wetzels JFM. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? Kidney Int. 2016;89(5):981–3.

    Article  CAS  Google Scholar 

  52. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1966–73.

    Article  Google Scholar 

  53. Thakral A, Klein-Gitelman MS. An update on treatment and management of pediatric systemic Lupus erythematosus. Rheumatol Ther. 2016;3(2):209–19.

    Article  Google Scholar 

  54. Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50(9):1551–8.

    Article  Google Scholar 

  55. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 1999;8(1):3–10.

    Article  CAS  Google Scholar 

  56. Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4(2):42–55.

    Article  CAS  Google Scholar 

  57. Tunnicliffe DJ, Singh-Grewal D, Chaitow J, Mackie F, Manolios N, Lin MW, et al. Lupus means sacrifices: perspectives of adolescents and young adults with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68(6):828–37.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Dell Medical School, University of Texas at Austin, Dell Children’s Medical Center of Central Texas, Pediatric Nephrology, Austin, TX, USA

    Kartik Pillutla

  2. Department of Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, CA, USA

    Kuang-Yu Jen

Authors
  1. Kartik Pillutla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kuang-Yu Jen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kartik Pillutla .

Editor information

Editors and Affiliations

  1. Department of Pediatric Nephrology, UC Davis Medical Center, Sacramento, CA, USA

    Maha N. Haddad

  2. Department of Pediatrics, Division of Nephrology, University of California San Francisco, San Francisco, CA, USA

    Erica Winnicki

  3. Department of Pediatrics, UC Davis Children’s Hospital, Sacramento, CA, USA

    Stephanie Nguyen

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pillutla, K., Jen, KY. (2019). Lupus Nephritis. In: Haddad, M., Winnicki, E., Nguyen, S. (eds) Adolescents with Chronic Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-97220-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97220-6_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97219-0

  • Online ISBN: 978-3-319-97220-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation